A pioneering urine test for lung cancer, developed by scientists at the University of Cambridge with funding from Cancer Research UK, could be implemented in the NHS within five years. This innovative test detects specific proteins from senescent cells, often referred to as 'zombie cells', which signal the presence of early-stage lung cancer. Currently, most cases are diagnosed at advanced stages, complicating treatment and reducing survival rates. Professor Ljiljana Fruk expressed optimism about the test's potential to make a significant impact on early diagnosis. The test has successfully validated its biomarker in human tissue, and researchers are also exploring its application for other lung diseases such as pulmonary fibrosis. While further clinical trials are required, the test represents a significant advancement in the early detection of lung cancer, which is crucial for improving patient outcomes. The research underscores the importance of developing new technologies for cancer detection as part of a broader effort to enhance healthcare.